Table 1.
Baseline subject characteristics by treatment group
| Characteristics | Cholecalciferol (n = 22) | Doxercalciferol (n = 25) | P |
|---|---|---|---|
| CKD, n | 0.51 | ||
| Stage 3 | 12 | 16 | |
| Stage 4 | 10 | 19 | |
| Gender, n | 0.20 | ||
| Female | 12 | 9 | |
| Male | 10 | 16 | |
| Race, n | 0.20 | ||
| African American | 166 | 12 | |
| White | 6 | 13 | |
| Cause of CKD, diabetes/hypertension/other causes, % | 36/40/24 | 50/31/18 | |
| Age, yr | 62 ± 10 | 65 ± 10 | 0.31 |
| Years of CKD | 4.2 ± 2.6 | 3.9 ± 2.7 | 0.73 |
| GFR (MDRD) | 29.6 ± 7.4 | 36.4 ± 10.7 | 0.02 |
| Creatinine, mg/dl | 2.56 ± 0.83 | 2.19 ± 0.50 | 0.08 |
| BMI | 34.8 ± 5.9 | 35.9 ± 8.6 | 0.60 |
| Albumin, mg/dl | 4.7 ± 0.5 | 4.7 ± 0.5 | 0.85 |
BMI, body mass index.